MX2008012481A - Derivado de glucopiranosida de fenilbencilo. - Google Patents
Derivado de glucopiranosida de fenilbencilo.Info
- Publication number
- MX2008012481A MX2008012481A MX2008012481A MX2008012481A MX2008012481A MX 2008012481 A MX2008012481 A MX 2008012481A MX 2008012481 A MX2008012481 A MX 2008012481A MX 2008012481 A MX2008012481 A MX 2008012481A MX 2008012481 A MX2008012481 A MX 2008012481A
- Authority
- MX
- Mexico
- Prior art keywords
- hydrogen atom
- alkyl group
- benzyl phenyl
- hydroxy
- glucopyranoside derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Se describe un derivado de glucopiranosida de bencilfenilo que tiene un excelente efecto inhibidor en la actividad SGLT1 y/o SGLT2 humano. Se describe en forma específica un compuesto representado por la fórmula general (I) o una sal farmacológicamente aceptable del mismo. (I) en donde R1 representa un átomo de hidrógeno, un grupo amino, un grupo hidroxi C1-C6 alquilo o similar; R2 representa un átomo de hidrógeno, o similar; R3 representa un grupo C1-C6 alquilo, un grupo hidroxi C1-C6 alquilo, o similar; R4 representa un átomo de hidrógeno, un grupo C2-C7 acilo o similar; R5, R6, R7 y R8 representan independientemente un átomo de hidrógeno, un grupo C1-C6, o similar (siempre que todos de R5, R6, R7 y R8 no representen un átomo de hidrógeno en una molécula); R9 representa un átomo de halógeno; n representa un número que fluctúa de 0 a 4; y X representa CH o N.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006213600 | 2006-08-04 | ||
PCT/JP2007/065231 WO2008016132A1 (en) | 2006-08-04 | 2007-08-03 | Benzyl phenyl glucopyranoside derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008012481A true MX2008012481A (es) | 2008-10-10 |
Family
ID=38997305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008012481A MX2008012481A (es) | 2006-08-04 | 2007-08-03 | Derivado de glucopiranosida de fenilbencilo. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20090137499A1 (es) |
EP (1) | EP2048150A4 (es) |
JP (3) | JP4249256B2 (es) |
KR (1) | KR20090040250A (es) |
CN (1) | CN101472937A (es) |
AU (1) | AU2007279616A1 (es) |
BR (1) | BRPI0708521A2 (es) |
CA (1) | CA2649044A1 (es) |
EA (1) | EA200870540A1 (es) |
IL (1) | IL194404A0 (es) |
MX (1) | MX2008012481A (es) |
NO (1) | NO20084127L (es) |
TW (1) | TW200817424A (es) |
WO (1) | WO2008016132A1 (es) |
ZA (1) | ZA200809543B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2009096503A1 (ja) * | 2008-01-31 | 2009-08-06 | Daiichi Sankyo Company, Limited | ベンジルフェニルグルコピラノシド誘導体 |
TWI523652B (zh) | 2008-07-15 | 2016-03-01 | 泰瑞克公司 | 氘化苄基苯衍生物及使用方法 |
BRPI0918841B8 (pt) * | 2008-08-28 | 2021-05-25 | Pfizer | derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos |
WO2011039108A2 (en) | 2009-09-30 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
KR20120087950A (ko) | 2009-10-20 | 2012-08-07 | 노파르티스 아게 | 글리코시드 유도체 및 그의 용도 |
US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
AP3099A (en) | 2009-11-02 | 2015-01-31 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol de derivatives |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
US8614195B2 (en) | 2011-04-14 | 2013-12-24 | Novartis Ag | Glycoside derivatives and uses thereof |
WO2012140596A1 (en) | 2011-04-14 | 2012-10-18 | Novartis Ag | Glycoside derivatives and uses thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
EP3141542B1 (en) | 2011-12-28 | 2020-05-27 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
TW201400495A (zh) * | 2012-04-03 | 2014-01-01 | Daiichi Sankyo Co Ltd | 具有螺環之c-醣苷衍生物 |
US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
AU2014213251B2 (en) | 2013-02-04 | 2017-07-20 | Taisho Pharmaceutical Co., Ltd. | Prophylactic or therapeutic drug for constipation |
AU2014240513B2 (en) | 2013-03-14 | 2017-02-09 | Mars, Incorporated | Flavor composition containing HMG glucosides |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
ES2852054T3 (es) | 2013-03-15 | 2021-09-10 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
SG11201507453VA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
MX2015011448A (es) | 2013-03-15 | 2016-06-06 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
DK2981269T3 (da) | 2013-04-04 | 2023-10-23 | Boehringer Ingelheim Vetmedica Gmbh | Behandling af stofskifteforstyrrelser hos hestedyr |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303098A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303097A1 (en) * | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
AU2014255727B2 (en) | 2013-04-18 | 2019-07-25 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
SI3862003T1 (sl) | 2013-12-17 | 2024-02-29 | Boehringer Ingelheim Vetmedica Gmbh | Inhibitor SGLT-2 za uporabo pri zdravljenju metabolične motnje pri mačjih živalih |
EP3485890B1 (en) | 2014-01-23 | 2023-05-10 | Boehringer Ingelheim Vetmedica GmbH | Sglt2 inhibitors for treatment of metabolic disorders in canine animals |
EP3868745A1 (en) | 2014-02-07 | 2021-08-25 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
PT3125882T (pt) * | 2014-04-01 | 2020-08-17 | Boehringer Ingelheim Vetmedica Gmbh | Tratamento de distúrbios metabólicos em animais equinos |
AU2015320975B2 (en) * | 2014-09-25 | 2020-10-08 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
EA201890592A1 (ru) | 2015-08-27 | 2018-09-28 | Бёрингер Ингельхайм Ветмедика Гмбх | Жидкие фармацевтические композиции, содержащие ингибиторы sglt-2 |
WO2017096230A1 (en) | 2015-12-04 | 2017-06-08 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
JP6812327B2 (ja) * | 2017-11-21 | 2021-01-13 | 株式会社日立製作所 | 治療選択支援システム及び方法 |
CN108191922A (zh) * | 2018-01-09 | 2018-06-22 | 中国科学院新疆理化技术研究所 | 药西瓜中苯甲醇苷类化合物及其制备方法 |
EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
CN113461502B (zh) * | 2021-07-15 | 2023-07-28 | 台州臻挚生物科技有限公司 | 2-羟基二苯甲酮类化合物及其卤化衍生物的制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4009208A (en) | 1970-08-07 | 1977-02-22 | Sterling Drug Inc. | N,n'-heptamethylenebis(4-methoxybenzamide) |
US4109000A (en) | 1975-01-22 | 1978-08-22 | Nippon Shinyaku Co., Ltd. | 5-benzylpicolinic acid derivatives |
SK287183B6 (sk) | 2000-03-17 | 2010-02-08 | Kissei Pharmaceutical Co., Ltd. | Glukopyranozyloxybenzylbenzenový derivát, farmaceutická kompozícia s jeho obsahom, ich použitie a medziprodukt |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
PT1329456E (pt) | 2000-09-29 | 2006-12-29 | Kissei Pharmaceutical | Derivados de glucopiranosiloxibenzilbenzeno e composições medicinais que os contêm. |
CA2429833A1 (en) | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
TWI255817B (en) | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
HUP0303249A3 (en) | 2001-02-22 | 2007-03-28 | Sankyo Co | Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them |
CN100376592C (zh) | 2001-06-20 | 2008-03-26 | 橘生药品工业株式会社 | 含氮的杂环衍生物、含有该衍生物的药物组合物、其药物应用以及用于该衍生物制备的中间体 |
WO2003011880A1 (fr) | 2001-07-31 | 2003-02-13 | Kissei Pharmaceutical Co., Ltd. | Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition |
TWI314455B (en) | 2002-12-10 | 2009-09-11 | Nippon Kayaku Kk | 3-phenyl-cinnoline derivatives and anti-tumor agent containing the same |
DE10258007B4 (de) * | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
CA2560005A1 (en) * | 2004-03-31 | 2005-10-13 | Kissei Pharmaceutical Co., Ltd. | Phenol derivative, medicinal composition containing the same, and medicinal use thereof |
-
2007
- 2007-08-02 TW TW096128337A patent/TW200817424A/zh unknown
- 2007-08-03 EP EP07791905A patent/EP2048150A4/en not_active Withdrawn
- 2007-08-03 MX MX2008012481A patent/MX2008012481A/es not_active Application Discontinuation
- 2007-08-03 JP JP2008527797A patent/JP4249256B2/ja not_active Expired - Fee Related
- 2007-08-03 CN CNA2007800223968A patent/CN101472937A/zh active Pending
- 2007-08-03 KR KR1020087023790A patent/KR20090040250A/ko not_active Application Discontinuation
- 2007-08-03 CA CA002649044A patent/CA2649044A1/en not_active Abandoned
- 2007-08-03 WO PCT/JP2007/065231 patent/WO2008016132A1/ja active Application Filing
- 2007-08-03 BR BRPI0708521-4A patent/BRPI0708521A2/pt not_active Application Discontinuation
- 2007-08-03 AU AU2007279616A patent/AU2007279616A1/en not_active Abandoned
- 2007-08-03 US US12/280,510 patent/US20090137499A1/en not_active Abandoned
- 2007-08-03 EA EA200870540A patent/EA200870540A1/ru unknown
-
2008
- 2008-09-08 JP JP2008229193A patent/JP4425318B2/ja not_active Expired - Fee Related
- 2008-09-28 IL IL194404A patent/IL194404A0/en unknown
- 2008-09-29 NO NO20084127A patent/NO20084127L/no not_active Application Discontinuation
- 2008-11-07 ZA ZA200809543A patent/ZA200809543B/xx unknown
-
2009
- 2009-02-18 JP JP2009035070A patent/JP2009108105A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20090040250A (ko) | 2009-04-23 |
EA200870540A1 (ru) | 2009-04-28 |
US20090137499A1 (en) | 2009-05-28 |
AU2007279616A1 (en) | 2008-02-07 |
JPWO2008016132A1 (ja) | 2009-12-24 |
EP2048150A4 (en) | 2011-06-29 |
JP2009024021A (ja) | 2009-02-05 |
IL194404A0 (en) | 2009-08-03 |
WO2008016132A1 (en) | 2008-02-07 |
CN101472937A (zh) | 2009-07-01 |
TW200817424A (en) | 2008-04-16 |
CA2649044A1 (en) | 2008-02-07 |
BRPI0708521A2 (pt) | 2011-05-31 |
EP2048150A1 (en) | 2009-04-15 |
NO20084127L (no) | 2009-04-30 |
JP4425318B2 (ja) | 2010-03-03 |
ZA200809543B (en) | 2010-03-31 |
JP2009108105A (ja) | 2009-05-21 |
JP4249256B2 (ja) | 2009-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2008012481A (es) | Derivado de glucopiranosida de fenilbencilo. | |
TW200730540A (en) | Novel peptide compounds | |
TW200642683A (en) | Heterocyclic compound | |
CO6210826A2 (es) | Nuevos derivados de isoquinolina e isoquinolinona sustituidos | |
MX2010013275A (es) | Compuesto novedoso de uracilo o su sal que tiene actividad inhibidora de desoxiuridin trifosfatasa de humano. | |
MY153910A (en) | BICYCLIC y-AMINO ACID DERIVATIVE | |
MX2009004096A (es) | Metabolitos de talarozol. | |
TW200616994A (en) | Novel thiophene derivatives | |
MY145408A (en) | Dihydropyrazolopyrimidinone derivatives | |
MX2009008756A (es) | Compuesto macrociclico. | |
RS20090249A (en) | Spiroketone acetyl-coa carboxylase inhibotors | |
TW200726470A (en) | 6,7-unsaturated-7-carbamoylmorphinan derivatives | |
WO2008087933A1 (ja) | IκBキナーゼβ阻害活性を有する新規インドール誘導体 | |
SG170049A1 (en) | Novel 11 beta - hydroxyandrosta-4-ene-3-ones | |
NO20054135L (no) | Kipolinon/benzoksazin derivater og anvendelser derav | |
MY139612A (en) | Benzoxazine derivatives as 5-th6 modulators and uses thereof | |
TW200714593A (en) | Agent for treatment of solid tumor | |
TW200637870A (en) | Novel pyrimidine nucleoside compound and salt thereof | |
MY136824A (en) | Substituted benzoxazinones and uses thereof | |
MXPA03009548A (es) | Arilsulfonamidas como agentes antivirales. | |
TW200720265A (en) | Agent for treatment of hematopoietic tumor | |
MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
WO2008110690A3 (fr) | Nouveaux derives indoliques, leurs procedes de preparation et leurs utilisations notamment en tant qu'antibacteriens | |
TW200745153A (en) | Trehalose compound and pharmaceutical comprising the compound | |
WO2008139845A1 (ja) | 新規アミド誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |